13.02.2014 • NewsrenewablesRenewable EnergyEEG

EU Opens Proceedings Against German Energy Rebates

As expected, the European Commission has opened proceedings against Germany for granting special privileges to energy-intensive companies under the renewable energy act (EEG) and ordered that the federal government end the rebates by Dec. 18, 2014.

Under the German regulations, companies with high energy costs are exempted from a large proportion of the levies on utility bills to support renewable energy. This also includes firms generating their own on-site energy.

Currently, around 2,000 companies, including many in the chemical industry, profit from the regulations, thereby collectively saving an estimated €500 billion annually.

The country's new economics minister, the Social Democrat Sigmar Gabriel, has said in the past that German industry stands to lose competitiveness if required to pay the full renewables levy. However, in a meeting with the minister on Feb. 11, industry representatives said he had offered no concessions to affected companies.

According to the German Federal Office of Economics and Export Control, 2,098 companies will profit from the energy rebates in 2014, some 378 more than in 2013.

The German chemical industry association, VCI, has called on the government to scale back its aid to renewables, saying that the targets have been more than met, while at the same time the security of energy supply is threatened and costs are exploding.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.